

# William B White

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1886410/william-b-white-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196  
papers

9,593  
citations

44  
h-index

94  
g-index

206  
ext. papers

11,112  
ext. citations

6.3  
avg, IF

6.22  
L-index

#	Paper	IF	Citations
196	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.. <i>Postgraduate Medicine</i> , <b>2022</b> ,	3.7	1
195	Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , <b>2021</b> , 1-8	4.6	0
194	Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. <i>Blood Pressure Monitoring</i> , <b>2021</b> , 27,	1.3	2
193	Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1006-1019	6.1	10
192	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1580-1587	6.7	5
191	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1612-1624	6.1	3
190	Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 1407-1409	6.9	0
189	Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 630-637	2.6	2
188	Effects of the oral testosterone undecanoate Kyzatrex <sup>™</sup> on ambulatory blood pressure in hypogonadal men. <i>Journal of Clinical Hypertension</i> , <b>2021</b> , 23, 1420-1430	2.3	4
187	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1742-1767	1.9	15
186	Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 187	8.7	1
185	Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.. <i>Kidney360</i> , <b>2021</b> , 2, 425-434	1.8	0
184	A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	32
183	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1462-1471	12.3	8
182	Response to Letter Regarding Article, "Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY)". <i>Circulation</i> , <b>2020</b> , 141, e652-e653	16.7	53
181	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e012797	6	12
180	The Silver Anniversary of Blood Pressure Monitoring. <i>Blood Pressure Monitoring</i> , <b>2020</b> , 25, 1	1.3	1

179	Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 1473-1476	1.2	2
178	Individual patient risk assessment and cost-benefit analysis of patiomer in AMBER - AuthorsPreply. <i>Lancet, The</i> , <b>2020</b> , 396, 311-312	4.0	
177	Patiomer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1540-1550	4.0	118
176	Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1633-1642	15.1	44
175	Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , <b>2019</b> , 58, 61-69	3.9	9
174	Effects of a State- and Use-Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 90-97	2.9	7
173	Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 1701-1710	6.9	13
172	Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). <i>Circulation</i> , <b>2019</b> , 140, 1626-1635	16.7	49
171	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , <b>2019</b> , 218, 66-74	4.9	12
170	Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 905-916	1.9	45
169	History and Justification of a National Blood Pressure Measurement Validated Device Listing. <i>Hypertension</i> , <b>2019</b> , 73, 258-264	8.5	29
168	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 382-391	3	7
167	Cardiovascular Safety of the Selective $\mu$ Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 309-317	2.6	8
166	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1022-1027	3.3	3
165	Cardiovascular Safety of the $\beta$ Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. <i>Journal of Clinical Pharmacology</i> , <b>2018</b> , 58, 1084-1091	2.9	11
164	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 947-956	1.9	2
163	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 398-405	6.9	18
162	Cardiorenal Safety of OTC Analgesics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 103-118	2.6	10

161	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 813-819.e5	2.4	14
160	A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. <i>Blood Pressure Monitoring</i> , <b>2018</b> , 23, 153-163	1.3	4
159	Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1200-1210	59.2	382
158	Timed mobility: description of measurement, performance, and dimensionality among older adults. <i>Disability and Rehabilitation</i> , <b>2018</b> , 40, 2011-2014	2.4	11
157	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 654-659	6.7	19
156	Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals. <i>Clinical Pharmacology in Drug Development</i> , <b>2018</b> , 7, 332-340	2.3	6
155	Management of Hypertension in Athletes <b>2018</b> , 49-67		
154	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1496-1505	3	3
153	Ambulatory blood pressure monitoring in the 21st century. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 1108-1111	2.3	21
152	Relationships among clinic, home, and ambulatory blood pressures with small vessel disease of the brain and functional status in older people with hypertension. <i>American Heart Journal</i> , <b>2018</b> , 205, 21-30	4.9	9
151	Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. <i>Journal of the American Society of Hypertension</i> , <b>2018</b> , 12, 768-778.e1		13
150	Longitudinal microstructural changes of cerebral white matter and their association with mobility performance in older persons. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194051	3.7	9
149	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009114	6	13
148	Cardiovascular Safety of Febuxostat. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1584	59.2	3
147	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , <b>2018</b> , 72, e53-e90	8.5	333
146	Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. <i>American Journal of Nephrology</i> , <b>2018</b> , 48, 172-180	4.6	17
145	Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	7
144	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 1510-1515	14.6	13

143	Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1111-1115	3	13
142	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 664-671	6.7	41
141	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). <i>Circulation</i> , <b>2017</b> , 135, 1911-1921	16.7	43
140	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 962-969	6.7	19
139	Functional reach of older adults: normative reference values based on new and published data. <i>Physiotherapy</i> , <b>2017</b> , 103, 387-391	3	22
138	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 695-701	2.3	6
137	Severe and resistant hypertension in an older woman with claudication. <i>Journal of the American Society of Hypertension</i> , <b>2017</b> , 11, 475-479		0
136	Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 761-768	1.9	9
135	Cardiovascular safety of therapies for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 13-25	4.1	5
134	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , <b>2016</b> , 68, 606-13	8.5	18
133	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1267-73	14.6	38
132	Cardiovascular Effects of Incretin-Based Therapies. <i>Annual Review of Medicine</i> , <b>2016</b> , 67, 245-60	17.4	20
131	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , <b>2016</b> , 175, 18-27	4.9	6
130	Ambulatory Blood Pressure Monitoring in Older Persons <b>2016</b> , 209-225		1
129	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 788-797	1.9	24
128	Exposure to Racial Discrimination and Ambulatory Blood Pressure in Women with Type 2 Diabetes. <i>Stress and Health</i> , <b>2016</b> , 32, 337-345	3.7	4
127	Severe and refractory hypertension in a young woman. <i>Journal of the American Society of Hypertension</i> , <b>2016</b> , 10, 506-9		2
126	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2016</b> , 2, 200-5	6.4	21

125	Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. <i>Journal of the American Society of Hypertension</i> , <b>2016</b> , 10, 755-762		20
124	Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. <i>Journal of the American Society of Hypertension</i> , <b>2016</b> , 10, 819-826		18
123	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , <b>2015</b> , 169, 486-95	4.9	20
122	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , <b>2015</b> , 385, 2067-76	4.0	551
121	Foreword. The 20th year of Blood Pressure Monitoring. <i>Blood Pressure Monitoring</i> , <b>2015</b> , 20, 1	1.3	
120	EXAMINE: targeting risk and treatment in diabetes - AuthorsPreply. <i>Lancet, The</i> , <b>2015</b> , 386, 1445	4.0	1
119	Managing hypertension with ambulatory blood pressure monitoring. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 2	4.2	15
118	Renal denervation therapy for hypertension: pathways for moving development forward. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 341-50		29
117	The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. <i>Drug Safety</i> , <b>2015</b> , 38, 33-54	5.1	75
116	Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , <b>2015</b> , 169, 197-204	4.9	18
115	Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 262-75.e9		296
114	Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , <b>2014</b> , 16, 541	4.2	13
113	Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. <i>Hypertension</i> , <b>2014</b> , 64, 731-7	8.5	92
112	Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 743-57		38
111	Thalamic fractional anisotropy predicts accrual of cerebral white matter damage in older subjects with small-vessel disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 1321-7	7.3	12
110	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 780-90		7
109	Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 14-26	2.3	588
108	Diagnostic evaluation: Ambulatory blood pressure monitoring in clinical hypertension management. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 939-41; quiz 942		5

107	Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , <b>2013</b> , 165, 477-88	4.9	27
106	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1327-35	59.2	1858
105	Review of the state of renal nerve ablation for patients with severe and resistant hypertension. <i>Journal of the American Society of Hypertension</i> , <b>2013</b> , 7, 484-93		14
104	Intensive versus standard ambulatory blood pressure lowering to prevent functional Decline in the Elderly (INFINITY). <i>American Heart Journal</i> , <b>2013</b> , 165, 258-265.e1	4.9	32
103	Response to Letter to the Editor by Blankfield regarding "Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium." <i>American Heart Journal</i> , <b>2013</b> , 166, e11	4.9	2
102	Rapid buildup of brain white matter hyperintensities over 4 years linked to ambulatory blood pressure, mobility, cognition, and depression in old persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2013</b> , 68, 1387-94	6.4	42
101	Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. <i>Journal of Clinical Hypertension</i> , <b>2013</b> , 15, 397-403	2.3	6
100	Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. <i>Chest</i> , <b>2013</b> , 144, 758-765	3.6	72
99	Response. <i>Chest</i> , <b>2013</b> , 144, 1082-1083	5.3	
98	Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. <i>Journal of Clinical Hypertension</i> , <b>2012</b> , 14, 284-92	2.3	37
97	The present and future of the American Society of Hypertension-2012. <i>Journal of Clinical Hypertension</i> , <b>2012</b> , 14, 401-3	2.3	
96	The present and future of the American Society of Hypertension: 2012. <i>Journal of the American Society of Hypertension</i> , <b>2012</b> , 6, 237-9		
95	A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. <i>American Heart Journal</i> , <b>2012</b> , 163, 27-32	4.9	47
94	Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. <i>American Heart Journal</i> , <b>2012</b> , 164, 14-20	4.9	40
93	Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?. <i>Current Hypertension Reports</i> , <b>2012</b> , 14, 366-73	4.7	11
92	Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. <i>Hypertension</i> , <b>2012</b> , 60, 310-8	8.5	51
91	Module 1: Historical review of evidence-based treatment of hypertension. <i>Journal of Family Practice</i> , <b>2012</b> , 61, S5-14; quiz S27	0.2	
90	EXamination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. <i>American Heart Journal</i> , <b>2011</b> , 162, 620-626.e1	4.9	123

89	The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 81-8	2.3	111
88	Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 506-16	2.3	18
87	Leadership message. American Society of Hypertension-designated centers of excellence: a new initiative. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 391-2	2.3	3
86	Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 467-72	2.3	85
85	Evaluation of the migraine treatment sumatriptan/naproxen sodium on blood pressure following long-term administration. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 910-6	2.3	6
84	Effects of naproxinod on blood pressure in patients with osteoarthritis. <i>American Journal of Cardiology</i> , <b>2011</b> , 107, 1338-45	3	15
83	Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. <i>Hypertension</i> , <b>2011</b> , 57, 413-20	8.5	167
82	Home blood pressure monitoring as an intervention to control hypertension: comment on "Home blood pressure management and improved blood pressure control". <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 1181-2		0
81	Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. <i>Circulation</i> , <b>2011</b> , 124, 2312-9	16.7	90
80	Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. <i>Blood Pressure Monitoring</i> , <b>2010</b> , 15, 205-12	1.3	37
79	When and how to use self (home) and ambulatory blood pressure monitoring. <i>Journal of the American Society of Hypertension</i> , <b>2010</b> , 4, 56-61		69
78	Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. <i>Journal of Clinical Hypertension</i> , <b>2010</b> , 12, 765-75	2.3	42
77	Effects of the cyclooxygenase inhibiting nitric oxide donator naproxinod versus naproxen on systemic blood pressure in patients with osteoarthritis. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 840-5 <sup>3</sup>		41
76	Matching the circadian rhythms of hypertension with pharmacotherapy. <i>Clinical Cardiology</i> , <b>2009</b> , 26, 10-15	3.3	78
75	Defining the problem of treating the patient with hypertension and arthritis pain. <i>American Journal of Medicine</i> , <b>2009</b> , 122, S3-9	2.4	28
74	The potential role of nitric oxide in cardiovascular safety when treating patients with osteoarthritis and hypertension: a moderated panel discussion. <i>American Journal of Medicine</i> , <b>2009</b> , 122, S23-5	2.4	3
73	Blood Pressure Monitoring enters its 14th year. <i>Blood Pressure Monitoring</i> , <b>2009</b> , 14, 1	1.3	
72	ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 850-5	2.3	55



71	Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 450-8	2.3	18
70	Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. <i>American Journal of Medicine</i> , <b>2008</b> , 121, S2-7	2.4	27
69	Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. <i>Journal of the American Society of Hypertension</i> , <b>2008</b> , 2, 20-7		8
68	Effects of metoprolol succinate extended release vs. amlodipine besylate on the blood pressure, heart rate, and the rate-pressure product in patients with hypertension. <i>Journal of the American Society of Hypertension</i> , <b>2008</b> , 2, 378-84		5
67	Early morning hypertension: what does it contribute to overall cardiovascular risk assessment?. <i>Journal of the American Society of Hypertension</i> , <b>2008</b> , 2, 397-402		57
66	Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. <i>Journal of the American Society of Hypertension</i> , <b>2008</b> , 2, 462-8		91
65	Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. <i>Hypertension</i> , <b>2008</b> , 52, 587-93	8.5	17
64	Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. <i>Blood Pressure Monitoring</i> , <b>2008</b> , 13, 123-9	1.3	20
63	Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. <i>Blood Pressure Monitoring</i> , <b>2008</b> , 13, 21-7	1.3	25
62	Importance of blood pressure control over a 24-hour period. <i>Journal of Managed Care Pharmacy</i> , <b>2007</b> , 13, 34-9		50
61	Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 91-8	3	151
60	Importance of aggressive blood pressure lowering when it may matter most. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 10J-16J	3	9
59	Cardiovascular risk, hypertension, and NSAIDs. <i>Current Pain and Headache Reports</i> , <b>2007</b> , 11, 428-35	4.2	13
58	Cardiovascular risk, hypertension, and NSAIDs. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 36-43	4.9	26
57	Cardiovascular effects of the cyclooxygenase inhibitors. <i>Hypertension</i> , <b>2007</b> , 49, 408-18	8.5	85
56	Smoking-related morbidity and mortality in the cardiovascular setting. <i>Preventive Cardiology</i> , <b>2007</b> , 10, 1-4		39
55	Clinical assessment of early morning blood pressure in patients with hypertension. <i>Preventive Cardiology</i> , <b>2007</b> , 10, 210-4		10
54	Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 25-30	2.3	7

53	Pharmacologic agents in the management of hypertension--nisoldipine coat-core. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 259-66	2.3	2
52	Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 876-82	2.3	8
51	Cardiovascular effects of the selective cyclooxygenase-2 inhibitors. <i>Sub-Cellular Biochemistry</i> , <b>2007</b> , 42, 145-58	5.5	4
50	Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. <i>Hypertension</i> , <b>2006</b> , 48, 246-53	8.5	96
49	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. <i>American Heart Journal</i> , <b>2006</b> , 151, 176-84	4.9	55
48	Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 626-33	2.3	35
47	Treatment of benign prostatic hyperplasia in hypertensive men. <i>Journal of Clinical Hypertension</i> , <b>2005</b> , 7, 212-7	2.3	9
46	Update on the drug treatment of hypertension in patients with cardiovascular disease. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 695-705	2.4	21
45	Acute pain in the tip of the index finger. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 1223-4	2.4	
44	Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. <i>Blood Pressure Monitoring</i> , <b>2005</b> , 10, 157-63 <sup>1,3</sup>		31
43	Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. <i>Circulation</i> , <b>2005</b> , 112, 1979-84	16.7	89
42	Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. <i>American Heart Journal</i> , <b>2004</b> , 148, 628-34	4.9	25
41	Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, 347-53	2.3	95
40	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. <i>American Journal of Therapeutics</i> , <b>2004</b> , 11, 244-50	1	57
39	Hypertension management: differing points of view: ambulatory blood pressure monitoring for every hypertensive patient: it's about time!: the argument against. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 710-3; quiz 714	2.3	1
38	Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. <i>Hypertension</i> , <b>2003</b> , 41, 1021-6	8.5	242
37	Ambulatory blood-pressure monitoring in clinical practice. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2377-8	59.2	90
36	Relevance of blood pressure variation in the circadian onset of cardiovascular events. <i>Journal of Hypertension</i> , <b>2003</b> , 21, S9-15	1.9	43

35	Clinical trial experience around the globe: focus on calcium-channel blockers. <i>Clinical Cardiology</i> , <b>2003</b> , 26, 117-11	3.3	20
34	Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportion. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 1439-41	3	49
33	Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 38-42	3	102
32	Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 411-8	3	158
31	OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, A11	2.3	3
30	Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 739-45 <sup>3</sup>	2.3	9
29	Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 425-30	3	197
28	Systolic versus diastolic blood pressure versus pulse pressure. <i>Current Cardiology Reports</i> , <b>2002</b> , 4, 463-74.2	4.2	19
27	Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. <i>Hypertension</i> , <b>2002</b> , 39, 929-34	8.5	123
26	Clinical utility of ambulatory blood pressure: perspectives for national insurance coverage. <i>Blood Pressure Monitoring</i> , <b>2002</b> , 7, 27-31	1.3	4
25	Chronopharmacology of cardiovascular therapy. <i>Blood Pressure Monitoring</i> , <b>2002</b> , 7, 199-207	1.3	16
24	Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. <i>American Heart Journal</i> , <b>2002</b> , 144, 657-65	4.9	8
23	Comparative effects of telmisartan in the treatment of hypertension. <i>Journal of Clinical Hypertension</i> , <b>2002</b> , 4, 20-5	2.3	2
22	Ambulatory blood pressure monitoring: technique and application in the study of cardiac dysfunction and congestive heart failure. <i>Congestive Heart Failure</i> , <b>2001</b> , 7, 319-324		2
21	Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women. <i>American Journal of Hypertension</i> , <b>2001</b> , 14, 942-9	2.3	25
20	Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. <i>American Journal of Hypertension</i> , <b>2001</b> , 14, 1239-47	2.3	19
19	Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. <i>Blood Pressure Monitoring</i> , <b>2001</b> , 6, 63-72	1.3	117
18	Cardiovascular risk and ambulatory blood pressure. <i>Current Hypertension Reports</i> , <b>1999</b> , 1, 509-11	4.7	1

17	Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 50S-55S	2.3	86
16	Chronotherapeutics for cardiovascular disease. <i>Drugs</i> , <b>1998</b> , 55, 631-43	12.1	46
15	Comments on the Study of Zannad et al. <i>American Journal of Hypertension</i> , <b>1997</b> , 10, 1190	2.3	
14	"Inappropriate" physician habits in prescribing oral nifedipine capsules in hospitalized patients. <i>American Journal of Hypertension</i> , <b>1996</b> , 9, 1035-9	2.3	13
13	Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 233-8	2.9	9
12	Long-term reproducibility of ambulatory blood pressure. <i>Journal of Hypertension</i> , <b>1994</b> , 12, 703-708	1.9	81
11	The role of ambulatory monitoring of the blood pressure for assessment of antihypertensive agents. <i>Journal of Clinical Pharmacology</i> , <b>1992</b> , 32, 524-8	2.9	7
10	Utilizing ambulatory blood pressure recordings to evaluate antihypertensive drug therapy. <i>American Journal of Cardiology</i> , <b>1992</b> , 69, 8E-12E	3	43
9	Accuracy and analysis of ambulatory blood pressure monitoring data. <i>Clinical Cardiology</i> , <b>1992</b> , 15, 1110-33	3.3	9
8	Methods of blood pressure determination to assess antihypertensive agents: are casual measurements enough?. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 45, 581-6	6.1	38
7	The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 44, 173-8	6.1	20
6	Ejaculatory failure and urinary dysfunction secondary to labetalol. <i>Journal of Urology</i> , <b>1988</b> , 139, 371-2	2.5	6
5	Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 39, 664-8	6.1	9
4	Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 39, 43-8	6.1	44
3	Severe, accelerated postpartum hypertension associated with hyperthyroinaemia. Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1986</b> , 93, 1297-9	3.7	6
2	Effects of chronic nitrendipine on casual (office) and 24-hour ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , <b>1985</b> , 38, 60-4	6.1	37
1	Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants. <i>Clinical Pharmacology and Therapeutics</i> , <b>1985</b> , 37, 387-90	6.1	29